A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT07681596 · readout in 1,168 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
101estimated
Sites
12
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-09 | estimated | When the study began enrolling |
| Primary completion | 2029-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Multiple Myeloma
Interventions
- Biological: AZD4045
- Drug: Daratumumab
- Drug: Aldesleukin
Primary outcomes
what the primary-completion date above is the date OFAdverse events (AEs) and serious AEs (SAEs)
measured Through study completion, an average of 2 years
Dose-limiting toxicities (DLT)
measured 28 days
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed